Key result
In Chinese patients with atrial fibrillation, dabigatran (1.89%/year) and rivaroxaban 20 mg daily (1.93%/year) were associated with lower ischemic stroke rates than warfarin (3.35-5.24%/year).
Why the study?
Do dabigatran and rivaroxaban reduce ischemic stroke and intracranial hemorrhage compared to warfarin in Chinese patients with nonvalvular atrial fibrillation?
Population
2,099 Chinese patients with nonvalvular atrial fibrillation from a real-world cohort.
Comparison
Non-vitamin K antagonist oral anticoagulants… vs Warfarin, stratified by quality of…
Design
Cohort
Follow-up
mean 21.7 ± 13.4 months
Authors
Loading...
May support NOAC preference over warfarin in Chinese AF; extends real-world data but leaves randomized confirmation open.
Cohort (n=2,099)
Do dabigatran and rivaroxaban reduce ischemic stroke and intracranial hemorrhage compared to warfarin in Chinese patients with nonvalvular atrial fibrillation?
In a real-world cohort of Chinese patients with nonvalvular atrial fibrillation, dabigatran and rivaroxaban were associated with lower rates of ischemic stroke and intracranial hemorrhage compared to warfarin, regardless of warfarin's time in therapeutic range.
Li et al. (2016) conducted a cohort in Nonvalvular atrial fibrillation (n=2,099). Dabigatran and rivaroxaban vs. Warfarin was evaluated on Ischemic stroke. In Chinese patients with atrial fibrillation, dabigatran (1.89%/year) and rivaroxaban 20 mg daily (1.93%/year) were associated with lower ischemic stroke rates than warfarin (3.35-5.24%/year).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: